Omitting cytogenetic assessment from routine treatment response monitoring in CML is safe

ConclusionWe conclude that it is safe to omit routine cytogenetics for response assessment during treatment and to only use molecular monitoring, in order to prevent ambiguous classifications, reduce costs and reduce the need for invasive bone marrow sampling. Cytogenetic re‐assessment should still be performed when molecular response is suboptimal.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - December 30, 2017 Category: Hematology Authors: Inge G.P. Geelen, Noortje Thielen, Jeroen J.W.M. Janssen, Mels Hoogendoorn, Tanja J.A. Roosma, Peter J.M. Valk, Otto Visser, Jan J. Cornelissen, Peter E. Westerweel Tags: Original Article Source Type: research